On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion.
Posting a small dataset on reading a preclinical wound-healing model. It is mine, it is uncontrolled, and the method is stated so it can be discounted appropriately.
What I would like is not agreement but a second dataset collected by someone with no stake in mine. If one exists I would rather read it than argue for this one.
The arithmetic in post #2 is right; the assumption feeding it is the part to check.
For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.
Scoping that to what I have actually seen rather than what I have read.
Answering the question the opening post raises rather than the one it answers.
BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a dismissal — it is the state of the literature, and any discussion that starts elsewhere is starting from something that is not there.
What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.
Everything in post #4 holds. The case it does not cover is the one I have.
Counterpoint on reading a preclinical wound-healing model, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
This follows post #6 rather than contradicting it.
The preclinical work is genuinely interesting and it is preclinical. A rodent tendon model is a model of a rodent tendon, and the translation record from that kind of model is poor.
I have seen it go both ways, which is why I hedge.
Following, with nothing to contribute beyond having asked the same thing elsewhere.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.
This is the sort of thing the wiki should carry and currently does not.
Reading a preclinical wound-healing model is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
The arithmetic in post #11 is right; the assumption feeding it is the part to check.
I have been on both sides of the reading a preclinical wound-healing model argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
Everything in post #16 holds. The case it does not cover is the one I have.
Whatever the answer on reading a preclinical wound-healing model turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
Narrowing post #16, because the general version has more than one answer.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
Coming back to post #16, because the follow-up matters more than the original answer.
I would keep reading a preclinical wound-healing model and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
Post #19 is right about the mechanism and I think understates the practical bit.
The practical version of reading a preclinical wound-healing model is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
Adding the measurement that post #20 says would settle it.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
That is a description of practice, not a recommendation of it.
My position on reading a preclinical wound-healing model is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Where I part company with post #22, and it is a narrow parting.
A note on how reading a preclinical wound-healing model gets discussed rather than on reading a preclinical wound-healing model itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Sensible. I would want the same detail before I acted on it either.
On post #22 — agreed on the reasoning, with one qualification.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
Adding a source would improve this post and I do not have one to hand.
The pentadecapeptide sequence is short and stable enough to survive conditions that would degrade a larger peptide, which is one of the few things about it that is well characterised.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
Everything in post #26 holds. The case it does not cover is the one I have.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.